Stock Price & Analysis

The S1 support level for CMPX Stock is $2.67 ,The R1 resistant level for CMPX Stock is $3.26.

As of the end of day on 2025-03-06, the price of CMPX Stock was $2.74.

The target price for CMPX Stock according to analyst rating is 10.50, with the highest price target at 12.00 and the lowest at 8.00. Analysts have a Strong Buy rating on CMPX Stock overall.

The market cap of CMPX is $383.0M.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing proprietary antibody-based therapeutics to treat multiple human diseases. The Company’s pipeline is comprised of three product candidates, such as CTX-009, CTX-471, and CTX-8371. The Company’s lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). The Company’s second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.

CMPX has a total of 32 employees.